Rheumatoid Arthritis (RA) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032


 In Rheumatoid arthritis (RA), the body's immune system attacks the lining of the joints, resulting in pain and inflammation. RA is a chronic systemic inflammatory disease, most frequently afflicting the synovial membranes of multiple joints. The most destructive element of the disease is abnormal growth and division of the cells of the synovium, which results in thickening of the synovium, eventually forming the pannus, a sheet of inflammatory tissue. The pannus invades the joint, destroys the articular cartilage and the subchondral bone, and erodes the ligaments and tendons. The destruction of bone eventually leads to laxity in tendons and ligaments. Fibrous ankylosis may form in the late stage of the disease. Under the strain of daily activities and other forces, bone and joint structure alterations result in deformities frequently seen in patients with RA. Rheumatoid factor is an immunoglobulin not generally found in the general population (only 1% to 2% of healthy people are seropositive), but found in 70% to 80% of adult patients with established RA and 50% of patients in the early stages of RA.

 

In the US, approximately 1.25 million adults have Rheumatoid arthritis (RA), representing 0.65% to 1% of the adult population. The prevalence of work disability associated with RA was around 35% to 40% in the USA.

 

The competitive landscape of Rheumatoid Arthritis (RA) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Rheumatoid Arthritis (RA) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Rheumatoid Arthritis (RA) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Rheumatoid Arthritis (RA) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          MabionCD20     Parexel Phase 3

2          Sarilumab and Adalimumab       Regeneron Pharmaceuticals            Phase 3

3          Filgotinib           Galapagos NV   Phase 3

4          Olokizumab       Hexal AG          Phase 3

5          Abatacept         Jiangsu Simcere Pharmaceutical Co., Ltd.            Phase 3

6          ABBV-154         AbbVie  Phase 2

7          Hemay007        Tianjin Hemay Pharmaceutical Co.,Ltd   Phase 2

8          PF-06650833    Pfizer    Phase 2

9          ABX464            Abivax S.A.       Phase 2

10        Remicade         Samsung Bioepis Co., Ltd.         Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more